Zacks: Brokerages Set $4.75 Target Price for InVivo Therapeutics Hldg (NVIV)

Shares of InVivo Therapeutics Hldg (NASDAQ:NVIV) have been given a consensus broker rating score of 2.00 (Buy) from the two analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and one has given a strong buy recommendation to the company.

Brokerages have set a 12 month consensus price target of $4.75 for the company and are forecasting that the company will post ($0.13) EPS for the current quarter, according to Zacks. Zacks has also given InVivo Therapeutics an industry rank of 166 out of 265 based on the ratings given to related companies.

How to Become a New Pot Stock Millionaire

NASDAQ NVIV opened at $0.50 on Wednesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.44 and a current ratio of 4.44. InVivo Therapeutics has a 52 week low of $0.45 and a 52 week high of $4.30.

InVivo Therapeutics (NASDAQ:NVIV) last issued its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. research analysts expect that InVivo Therapeutics will post -0.56 EPS for the current year.

WARNING: “Zacks: Brokerages Set $4.75 Target Price for InVivo Therapeutics Hldg (NVIV)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI; and Therapeutic Trails injection program for the treatment of chronic SCI.

Get a free copy of the Zacks research report on InVivo Therapeutics (NVIV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for InVivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVivo Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply